Perampanel in the additional therapy of focal and primary generalized tonic-clonic seizures in children 4–12 years old: clinical data, experience of use and practical recommendations
https://doi.org/10.17749/2077-8333/epi.par.con.2021.087
Abstract
On March 18, 2021, an online council of experts in the field of epilepsy treatment was held, dedicated to the use of perampanel in the additional therapy of focal seizures (FS) and primary generalized tonic-clonic seizures (PGTCS) in children 4–12 years old. During the event, the features of the use of perampanel in this group of patients were discussed, considering the specifics of everyday clinical practice, current possibilities of PGTCS and FS therapy in children, its goals, as well as unsolved problems in the treatment of pediatric patients with PGTCS and FS. Particular attention was paid to the role of perampanel in the treatment of PGTCS and FS in children and its effectiveness in specific types of focal seizures.
Keywords
epilepsy,
children,
therapy features,
primary generalized tonic-clonic seizures,
focal seizures,
perampanel,
clinical practice,
quality of life
Supporting agencies: This article was published with the financial support of Eisai Co., Ltd. The authors are fully responsible for the content of the article and editorial decisions.
For citations:
Mukhin K.Yu., Belousova E.D., Burd S.G., Barkhatov M.V., Ermolenko N.A., Zyryanov S.K., Karpovich E.I., Morozova E.A., Odintsova G.V. Perampanel in the additional therapy of focal and primary generalized tonic-clonic seizures in children 4–12 years old: clinical data, experience of use and practical recommendations. Epilepsy and paroxysmal conditions. 2021;13(2):180-187. (In Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2021.087
Views:
698
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
